Formulation Development
Brammer Bio Announces Progress on $200-Million Program to Advance Gene Therapies
Brammer Bio recently announced that a 3-year, $200-million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.
Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies
GB Sciences, Inc. and Catalent Pharma Solutions recently announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients (APIs) for its Parkinson’s disease therapies.
Inovio Develops Novel H3N2 Influenza DNA Vaccine; Generates Cross-Reactive Responses & Provides Complete Protection Against Lethal Preclinical Challenges
Inovio Pharmaceuticals, Inc. recently announced its SynCon vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains…
ContraVir Pharmaceuticals Announces Completion of Phase 1 With CRV431
ContraVir Pharmaceuticals, Inc. recently announced that the primary endpoints of safety and tolerability were met in a single ascending dose (SAD) study of CRV431 conducted…
Neurimmune Achieves Milestone in Collaboration With Ono Pharmaceutical
Neurimmune recently announced the achievement of a key preclinical milestone in the ongoing collaboration with Ono Pharmaceutical Co., Ltd. In November 2017, the parties entered…
Lonza Launches Early-Intermediates Supply Initiative for Small-Molecule APIs
Lonza Pharma & Biotech recently announced the launch of its pharmaceutical early-intermediates supply initiative. The initiative leverages chemical production facilities at the company’s Visp (CH)…
Thermo Fisher Scientific to Launch Global Customer Solution Centers
Thermo Fisher Scientific Inc. recently announced its intent to open multiple Global Customer Solution Centers. The new Global Customer Solution Centers will focus on meeting and exceeding the demands of scientists in food, beverage, pharmaceutical and biotech laboratories by developing critical workflows and integrated solutions that help advance chromatography and mass spectrometry worldwide.
Molecular Templates Announces Agreement With Takeda for Joint Development of Protein-Based Oncology Therapy
Molecular Templates, Inc. recently announced an agreement with Takeda Pharmaceutical Company Limited for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma.
Evonik Completes Multi-Million Dollar Expansion of its CMO Capabilities for API & Advanced Intermediates
Evonik, a global CMO leader for API and advanced intermediates, recently announced the completion of a 36-million euro expansion of its contract manufacturing capabilities in the US and Europe.
SAMDI Tech Increases Clients’ Opportunities for Drug Candidate Hit Finding With Charles River Partnership
SAMDI Tech, Inc., the industry’s leading provider of label-free drug discovery solutions, has partnered with Charles River Laboratories, which provides products and services that accelerate…
IMV Announces Phase 2 Basket Trial in Collaboration With Merck
IMV Inc. recently announced it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low-…
Telix Completes Acquisition of Atlab for Prostate Cancer Program
Telix Pharmaceuticals Limited recently announced completion of the acquisition of Atlab Pharma SAS. The option to acquire Atlab for the consideration of $10 million (in…
Pfanstiehl Launches New cGMP-Produced, Parenteral-Grade Arginine for Biopharmaceutical & Pharmaceutical Formulations
As Pfanstiehl approaches its 100th anniversary in 2019, the company has launched a new high purity, low endotoxin, and low metal L-Arginine (USP, EP, JP,…
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate
VistaGen Therapeutics, Inc. and Pherin Pharmaceuticals, Inc. recently announced the signing of a license agreement granting VistaGen exclusive worldwide rights to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed (PRN) treatment of Social Anxiety Disorder (SAD).
Inoviem Scientific Enters Into Service-Based Partnership With XoNovo
Inoviem Scientific recently announced a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company developing a proprietary small molecule for the treatment of neurodegenerative diseases. Financial…
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial
Opiant Pharmaceuticals, Inc. recently announced it has completed patient enrollment in its Phase 2 clinical trial of OPTN001, a naloxone nasal spray, for the treatment…
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial
Pieris Pharmaceuticals, Inc. recently announced it has dosed the first patient in the company’s Phase 1 combination clinical trial of PRS-343, its lead proprietary immuno-oncology…
MilliporeSigma Launches Next-Generation Process Technologies for Intensified Drug Production
MilliporeSigma recently launched three new products to help biomanufacturers navigate the evolving biopharma landscape with increased speed, greater flexibility, and enhanced quality. These next-generation process…
Aucta Pharmaceuticals Signs Commercial Manufacturing Agreement With Catalent
Catalent Pharma Solutions recently announced a commercial supply agreement for Aucta Pharmaceuticals, Inc.’s (Aucta) vigabatrin. The agreement follows a successful development program to formulate vigabatrin…
Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration With AstraZeneca
Biothera Pharmaceuticals, Inc. recently announced a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI) can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.
